arrow
P

Peter Grimison

nsw health
H指数:39
被引数:5,127

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Efficacy and feasibility of treating adults with paediatric chemotherapy protocols in Ewing sarcoma, rhabdomyosarcoma and osteosarcoma – a systematic review by the Australia and New Zealand Sarcoma Association clinical practice guidelines working party

治疗成人的儿科化疗方案在尤文氏肉瘤、横纹肌肉瘤和骨肉瘤中的有效性和可行性——澳大利亚和新西兰肉瘤协会临床实践指南工作组系统评价

2026-03-260
OAAI
Extracranial, Extragonadal Germ Cell Tumors: A Multicenter Australian Case Series

颅外、生殖腺外生殖细胞瘤:一项多中心澳大利亚病例系列研究

2026-01-010
OAAI
The role of multivisceral resection on outcomes in primary retroperitoneal sarcoma: A systematic review by the Australian and New Zealand Sarcoma Association Clinical Practice Guidelines Working Party

多器官联合切除术在原发性腹膜后肉瘤预后中的作用:澳大利亚和新西兰肉瘤协会临床实践指南工作组系统评价

2025-12-010
OA
Development and validation of a prognostic model incorporating patient reported outcomes for advanced gastric and esophageal carcinoma (AGOC) using individual patient data from two AGITG randomized clinical trials

基于两项AGITG随机临床试验的个体患者数据,开发并验证一个整合患者报告结局的预后模型,用于预测晚期胃癌和食管癌(AGOC)。

2025-09-160
OAAI
A phase 4, multicenter, global clinical study to evaluate discontinuation and rechallenge of pexidartinib in patients with tenosynovial giant cell tumor previously treated with pexidartinib
CANCER
IF5.1
2024-11-121
OAAI
A signal-seeking phase 2 study of Trastuzumab emtansine in tumours harbouring HER2 amplification or mutation
2024-09-091
OAAI
Pembrolizumab with Chemoradiation as Treatment for Muscle-invasive Bladder Cancer: Analysis of Safety and Efficacy of the PCR-MIB Phase 2 Clinical Trial (ANZUP 1502)
2024-06-012
PRE
Impact of teratoma on survival probabilities of patients with metastatic non-seminomatous germ cell cancer: Results from the IGCCCG Update Consortium

畸胎瘤对转移性非精原细胞性生殖细胞癌患者生存概率的影响: IGCCCG更新联盟的结果

2024-05-010
PRE